Tumor rejection antigen P1A is tightly regulated and is restricted to immune privileged organs such as testis and some lineages of cancer cells including myeloma cells. We have studied P1A-specific cytotoxic T lymphocytes (CTL) responses in a mouse plasmacytoma (J558) model. We showed that P1A-specific CTLs could be efficiently activated in vivo and under optimal conditions, P1A-specific CTL cells can completely eliminate established large P1A+ myeloma. Recently we have successfully cloned the human P1A gene from human cancer cells. Preliminary studies suggest that human P1A is preferentially expressed in myeloma cells but not in normal human tissues. Using human-P1A expressing adenovirus to immunize HLA-A2 transgenic mice, we have found that a few A2-binding peptides can stimulate immune splenocytes to produce IFN-gamma, these epitopes can thus be potentially targeted by CTL in human cancer patients.
我公司新研发的Tumor rejection antigen P1A(肿瘤排斥抗原P1A)抗体已经通过检验测试已经通过检验测试，可以应用于蛋白印迹（WB），免疫组化（IHC），免疫细胞化学（ICC），酶联免疫吸附试验（ELISA），免疫沉淀（IP），免疫荧光（IF）实验。具体信息如下：
编号 产品名称
PR-1012， Tumor rejection antigen P1A Antibody
热忱欢迎国内外科研工作者联系订购！
镇江厚普生物科技有限公司销售部
2015-10-28